Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

IMGN

ImmunoGen (IMGN)

ImmunoGen Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:IMGN
FechaHoraFuenteTítuloSímboloCompañía
22/02/202415:15Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:IMGNImmunoGen Inc
14/02/202416:01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IMGNImmunoGen Inc
12/02/202415:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMGNImmunoGen Inc
12/02/202415:33Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:IMGNImmunoGen Inc
12/02/202408:32Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:IMGNImmunoGen Inc
12/02/202406:52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMGNImmunoGen Inc
12/02/202406:37PR Newswire (US)AbbVie Completes Acquisition of ImmunoGenNASDAQ:IMGNImmunoGen Inc
05/02/202415:10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IMGNImmunoGen Inc
01/02/202415:30Business WireImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IMGNImmunoGen Inc
29/01/202416:01Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:IMGNImmunoGen Inc
12/01/202410:10PR Newswire (US)Kuehn Law Encourages PXD, IMGN, HA and ICVX Investors to Contact Law FirmNASDAQ:IMGNImmunoGen Inc
02/01/202417:10PR Newswire (US)Kuehn Law Encourages CERE, HA, IMGN, and WAVD Investors to Contact Law FirmNASDAQ:IMGNImmunoGen Inc
02/01/202415:26Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:IMGNImmunoGen Inc
21/12/202315:52Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:IMGNImmunoGen Inc
19/12/202318:00Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:IMGNImmunoGen Inc
10/12/202311:00Business WireImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASHNASDAQ:IMGNImmunoGen Inc
08/12/202305:23IH Market NewsApple Boosts Vietnam Production, Broadcom Revenue Miss, Stellantis Job Cuts – Latest UpdatesNASDAQ:IMGNImmunoGen Inc
05/12/202306:46Dow Jones NewsImmunogen Gets FDA Priority Review of Elahere Full ApprovalNASDAQ:IMGNImmunoGen Inc
30/11/202307:42Dow Jones NewsImmunoGen Shares Soar Premarket on Takeover by AbbVieNASDAQ:IMGNImmunoGen Inc
30/11/202307:13Dow Jones NewsAbbVie to Buy ImmunoGen for More Than $10 BillionNASDAQ:IMGNImmunoGen Inc
30/11/202306:30PR Newswire (US)AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor PortfolioNASDAQ:IMGNImmunoGen Inc
02/11/202315:30Business WireImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare ConferenceNASDAQ:IMGNImmunoGen Inc
02/11/202315:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMGNImmunoGen Inc
02/11/202305:30Business WireImmunoGen Reports Recent Progress and Third Quarter 2023 Financial ResultsNASDAQ:IMGNImmunoGen Inc
27/10/202305:30Business WireImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian CancerNASDAQ:IMGNImmunoGen Inc
23/10/202307:30PR Newswire (US)Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory BoardNASDAQ:IMGNImmunoGen Inc
19/10/202315:01Business WireImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating ResultsNASDAQ:IMGNImmunoGen Inc
28/09/202306:00Business WireELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian CancerNASDAQ:IMGNImmunoGen Inc
19/09/202316:37Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMGNImmunoGen Inc
18/09/202305:30Business WireImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial OfficerNASDAQ:IMGNImmunoGen Inc
 Showing the most relevant articles for your search:NASDAQ:IMGN